comparemela.com
  1. Home
  2. Live Updates
  3. Sun Yat Sen University Cancer Center - Breaking News

Latest Breaking News On - Sun yat sen university cancer center - Page 15 : comparemela.com

Alternative Drug Combo Option in Nasopharyngeal Carcinoma?

Alternative Drug Combo Option in Nasopharyngeal Carcinoma?
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.

Sun yat sen university cancer centerNational key researchNational natural science foundation of chinaDevelopment program of chinaLi ting liuDevelopment programNational natural science foundation

Adjuvant Gemcitabine-Cisplatin Improves PFS in Nasopharyngeal Carcinoma

Gemcitabine plus cisplatin provides benefits over 5-fluorouracil plus cisplatin as adjuvant treatment for nasopharyngeal carcinoma.

Lin quan tangSun yat sen university cancer centerLiul t

The U S FDA Approved the Phase I/II Clinical Trial Application to Evaluate LBL-033, An Anti-MUC16/CD3 Bispecific Antibody Developed by Leads Biolabs, in Advanced Solid Tumors Including Ovarian Cancer

/PRNewswire/ Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs" or "Company") today announces that the phase I/II clinical trial.

United statesCharles caiNational medical products administration onBiolabs or companyBiolabs co ltdDrug administrationSun yat sen university cancer centerChief medical officerLeads biolabsNational medical products administrationSun yat sen university cancer

Dizal Leads China s Biotech Innovation by Showcasing Strength of its Oncology Pipeline at 2023 ASCO

Two highly anticipated oral presentations captured attention: first pivotal study of sunvozertinib (WU-KONG6) and multinational pivotal study of golidocitinib.

United statesXiaolin zhangQingqing caiMengzhao wangJames chih hsin yangPrnewswire dizalYan xuBusiness developmentAmerican society of clinical oncologyNational taiwan university hospitalChina national medical products administrationNational taiwan university cancer centerUnion medical college hospitalSun yat sen university cancer centerClinical oncologyAnnual meeting

Biosyngen s Cell Therapy BRG01 Granted Orphan Drug Designation by the U S FDA for Treatment of Nasopharyngeal Cancer

SINGAPORE, June 6, 2023 PRNewswire Jun. 1st, 2023, Biosyngen Pte. Ltd. (hereinafter as Biosyngen) announced that the U.S. Food and Drug Administrations (FDA) Office of Orphan Products Dev

United statesPrnewswire junBiosyngen pteOffice of orphan products developmentSun yat sen university cancer centerDrug administrationHannover medical schoolWorld health organizationOrphan products developmentOrphan drug designationDrug designationFast tract designation requestSouth china

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.